Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Multiple Myeloma
DRUG: CBG002 CAR-T Cell Suspension
AEs., The severity and incidence of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)., 2 years post infusion|DLT, The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and are specifically defined in study protocol., 28 days post infusion
Overall Response Rate (ORR), ORR at 3 months post infusion as evaluated by the Investigator, 3 months post infusion|Progression free survival (PFS), The time from cell infusion to the first assessment of tumor progression or death from any cause, 2 years post infusion|Overall survival (OS), The time from cell infusion to death due to any cause, 2 years post infusion|Duration of remission (DOR), The time from the first assessment of the tumor for complete response and above efficacy to the first assessment of disease progression or death of any cause, 2 years post infusion
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.